Home » ENCYSIVE SUBMITS THELIN RESPONSE TO FDA

ENCYSIVE SUBMITS THELIN RESPONSE TO FDA

May 25, 2006

Shares of Encysive Pharmaceuticals Inc. soared in early trading on Thursday as the pharmaceutical company said it submitted a complete response to the U.S. Food and Drug Administration regarding the company's new drug application for Thelin.
The Houston Chronicle

KEYWORDS FDAnews Drug Daily Bulletin

10Mar
FDA Drug GMP Facility Inspections During the Pandemic
16Mar
Pharmaceutical Naming Regulation: Understanding the Latest Developments
18Mar
Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19
23Mar
Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges
30Mar
Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges
06Apr
Medical Device Cybersecurity: Understand the Latest Developments

ENCYSIVE SUBMITS THELIN RESPONSE TO FDA

Upcoming Events

FDA Drug GMP Facility Inspections During the Pandemic

Pharmaceutical Naming Regulation: Understanding the Latest Developments

Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

UK Study Says Single Shot of Pfizer/BioNTech Vaccine Significantly Lessened Asymptomatic Infections

Eurofins Receives FDA Emergency Authorization for Over-the-Counter COVID-19 Test

Vetex Medical’s Thrombectomy Catheter Cleared by FDA

Merck Purchases Rights to Debiopharm’s Xevinapant for More Than $1 Billion

The Revised ICH E8: A Guide to New Clinical Trial Requirements